Q1 EPS Estimates for Teladoc Health Raised by Zacks Research

Teladoc Health, Inc. (NYSE:TDOC) – Stock analysts at Zacks Research lifted their Q1 2026 earnings estimates for Teladoc Health in a research report issued to clients and investors on Wednesday, March 11th. Zacks Research analyst Team now anticipates that the health services provider will earn ($0.36) per share for the quarter, up from their prior estimate of ($0.37). The consensus estimate for Teladoc Health’s current full-year earnings is ($1.16) per share. Zacks Research also issued estimates for Teladoc Health’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.99) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.26) EPS, Q4 2027 earnings at ($0.17) EPS, FY2027 earnings at ($1.02) EPS and FY2028 earnings at ($0.56) EPS.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The firm had revenue of $642.27 million for the quarter, compared to analyst estimates of $635.33 million. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The company’s quarterly revenue was up .3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.28) earnings per share. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS.

A number of other research firms also recently weighed in on TDOC. Oppenheimer decreased their price target on shares of Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 3rd. Wells Fargo & Company reduced their price objective on shares of Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday, February 26th. Stifel Nicolaus decreased their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. Deutsche Bank Aktiengesellschaft raised shares of Teladoc Health from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Tuesday. Finally, Canaccord Genuity Group dropped their price target on shares of Teladoc Health from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Teladoc Health presently has a consensus rating of “Hold” and an average target price of $7.72.

Teladoc Health Stock Performance

TDOC opened at $5.38 on Friday. The stock’s 50 day simple moving average is $5.62 and its 200-day simple moving average is $7.06. The company has a current ratio of 2.77, a quick ratio of 2.67 and a debt-to-equity ratio of 0.72. The stock has a market cap of $958.90 million, a PE ratio of -4.71 and a beta of 2.13. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $9.77.

Hedge Funds Weigh In On Teladoc Health

Institutional investors have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its position in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after buying an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Teladoc Health by 177.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after buying an additional 2,810 shares in the last quarter. Aster Capital Management DIFC Ltd raised its stake in shares of Teladoc Health by 101.1% in the third quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after acquiring an additional 2,425 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Teladoc Health in the fourth quarter valued at approximately $45,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Teladoc Health in the 3rd quarter worth approximately $58,000. 76.82% of the stock is owned by institutional investors.

Insider Activity

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of Teladoc Health stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. This trade represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.58% of the company’s stock.

More Teladoc Health News

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Zacks Research raised several near‑term and multi‑year EPS estimates (improvements to Q1–Q4 2026, FY2026 and FY2027), which narrows expected losses and helps valuation/earnings outlook. Zacks Research coverage
• Positive Sentiment: Deutsche Bank upgraded TDOC to Buy, citing BetterHelp momentum, AI initiatives and international expansion — contributing to renewed analyst interest that can lift demand. Deutsche Bank upgrade
• Positive Sentiment: Coverage pieces highlight an earnings beat and strategic plans (BetterHelp, AI, international) that have put TDOC back on investors’ radar and supported recent short‑term gains. Valuation analysis
• Neutral Sentiment: Market notes point to volatility and short‑term moves relative to the broader market — useful context for traders but not a direct company catalyst. Market note
• Negative Sentiment: JPMorgan lowered its price target from $9 to $7 and assigned a “neutral” rating — a reduction in expected upside that can weigh on sentiment even though the new target still implies upside from current levels. JPMorgan note
• Negative Sentiment: Insider selling: CEO Charles Divita III sold 27,731 shares at ~$5.49 (disclosed in an SEC filing), reducing his stake by ~7% — a sell by the CEO that some investors may view negatively. SEC filing

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.